NCT07095205View on ClinicalTrials.gov

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

PHASE4RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Nicotine transdermal patch

The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).

DRUG

PET Scan with [18F] VAT

All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Trial Locations (1)

11794

RECRUITING

Stony Brook University: Dept of Psychiatry, Stony Brook

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Stony Brook University

OTHER